Day One Biopharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.dayonebio.com

Moat Score

Market Cap $1.12B
PE -13
Debt -
Cash $422.77M
EV -
FCF -$90.24M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$84.29M
EBIT	-$211.46M
ROE	-15%
ROA	-35%
FCF	-$90.24M
Equity	$555.46M
Growth Stability	1
PE	-13.3
PB	2.02
P/FCF	-12.42
Price/Cash	0.38
Net Margins	-29%
Equity CAGR	9%
Earnings Growth YoY	-180%

Earnings Growth QoQ	-940%
Equity CAGR 5Y	9%
Equity CAGR 3Y	11%
Market Cap	$1.12B
Assets	$600.81M
Cash	$422.77M
Shares Outstanding	90.16M
Moat Score	2%
Working Capital	541.25M
Current Ratio	14.62
Shares Growth 3y	20%
Equity Growth QoQ	81%
Equity Growth YoY	43%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

SEC Filings

Direct access to Day One Biopharmaceuticals, Inc. (DAWN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Day One Biopharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Day One Biopharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Day One Biopharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Day One Biopharmaceuticals, Inc..

Years

Calculation mode

= -$902M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$90M	-$902M
DCF		-$82M	-$75M	-$68M	-$62M	-$56M	-$51M	-$46M	-$42M	-$38M	-$35M	-$348M
Value	-$902M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-29%
ROA	-	-30%	-25%	-42%	-55%	-35%
ROE	-	81%	-26%	-43%	-55%	-15%

Bad Net Margins (-29.21%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-
Earnings YoY growth	-	158%	66%	95%	33%	-
Equity YoY growth	-	408%	-619%	18%	4%	9%
FCF YoY growth	-	201%	257%	126%	34%	-